Clinical Trial

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \[68Ga\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-10.
Trial Details
NCT Number NCT07702292
Lead Sponsor Blue Earth Diagnostics
Collaborators: Medpace, Inc.
Conditions Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC), Invasive Lobular Breast Carcinoma
Enrollment 65 participants
Start Date 2026-06-30
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-15